Røsand Øystein, Høydal Morten Andre
Group of Molecular and Cellular Cardiology, Department of Circulation and Medical Imaging, Faculty of Medicine and Health, Norwegian University of Technology and Science (NTNU), 7030 Trondheim, Norway.
Diagnostics (Basel). 2021 Feb 9;11(2):269. doi: 10.3390/diagnostics11020269.
Ischemic heart disease (IHD) is the primary cause of death globally. IHD is associated with the disruption of blood supply to the heart muscles, which often results in myocardial infarction (MI) that further may progress to heart failure (HF). Exosomes are a subgroup of extracellular vesicles that can be secreted by virtually all types of cells, including cardiomyocytes, cardiac fibroblasts, endothelial cells, and stem and progenitor cells. Exosomes represent an important means of cell-cell communication through the transport of proteins, coding and non-coding RNA, and other bioactive molecules. Several studies show that exosomes play an important role in the progression of IHD, including endothelial dysfunction, the development of arterial atherosclerosis, ischemic reperfusion injury, and HF development. Recently, promising data have been shown that designates exosomes as carriers of cardioprotective molecules that enhance the survival of recipient cells undergoing ischemia. In this review, we summarize the functional involvement of exosomes regarding IHD. We also highlight the cardioprotective effects of native and bioengineered exosomes to IHD, as well as the possibility of using exosomes as natural biomarkers of cardiovascular diseases. Lastly, we discuss the opportunities and challenges that need to be addressed before exosomes can be used in clinical applications.
Diagnostics (Basel). 2021-2-9
Biomed Pharmacother. 2019-10-3
Eur Heart J. 2017-5-7
Am J Physiol Heart Circ Physiol. 2017-9-1
Front Immunol. 2024
Adv Exp Med Biol. 2017
J Cardiovasc Transl Res. 2018-9-2
Eur J Pharmacol. 2022-4-5
Exp Biol Med (Maywood). 2025-5-21
Stem Cell Res Ther. 2025-5-19
Curr Cardiol Rep. 2025-3-20
Mil Med Res. 2025-2-11
Stem Cell Res Ther. 2025-2-7
Curr Med Chem. 2024-5-3
Adv Exp Med Biol. 2023
Pharmaceuticals (Basel). 2020-8-4
Nat Rev Cardiol. 2020-12
J Cell Mol Med. 2020-7
Front Cell Dev Biol. 2020-3-6
Transl Stroke Res. 2021-2
Front Cell Dev Biol. 2019-12-4